AU2012212088B2 - Alpha-ketoheterocycles and methods of making and using - Google Patents

Alpha-ketoheterocycles and methods of making and using

Info

Publication number
AU2012212088B2
AU2012212088B2 AU2012212088A AU2012212088A AU2012212088B2 AU 2012212088 B2 AU2012212088 B2 AU 2012212088B2 AU 2012212088 A AU2012212088 A AU 2012212088A AU 2012212088 A AU2012212088 A AU 2012212088A AU 2012212088 B2 AU2012212088 B2 AU 2012212088B2
Authority
AU
Australia
Prior art keywords
compound
mhz
nmr
heteroaryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012212088A
Other languages
English (en)
Other versions
AU2012212088A1 (en
Inventor
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2012212088A1 publication Critical patent/AU2012212088A1/en
Application granted granted Critical
Publication of AU2012212088B2 publication Critical patent/AU2012212088B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012212088A 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using Ceased AU2012212088B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161439415P 2011-02-04 2011-02-04
US61/439,415 2011-02-04
PCT/US2012/023718 WO2012106569A1 (en) 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using

Publications (2)

Publication Number Publication Date
AU2012212088A1 AU2012212088A1 (en) 2013-08-08
AU2012212088B2 true AU2012212088B2 (en) 2016-07-14

Family

ID=46603088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012212088A Ceased AU2012212088B2 (en) 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using

Country Status (6)

Country Link
US (1) US9504675B2 (enExample)
EP (1) EP2670245B1 (enExample)
JP (1) JP5871957B2 (enExample)
AU (1) AU2012212088B2 (enExample)
CA (1) CA2825700A1 (enExample)
WO (1) WO2012106569A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825700A1 (en) 2011-02-04 2012-08-09 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using
TWI631097B (zh) 2012-07-27 2018-08-01 百健Ma公司 作爲s1p調節劑及/或atx調節劑之化合物
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
CN113004193B (zh) * 2021-02-07 2024-10-18 兰州康鹏威耳化工有限公司 硅化合物在环合反应中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044169A2 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2010005572A2 (en) 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
WO2010039186A2 (en) * 2008-09-23 2010-04-08 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CA2825700A1 (en) 2011-02-04 2012-08-09 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using

Also Published As

Publication number Publication date
EP2670245B1 (en) 2015-09-09
JP5871957B2 (ja) 2016-03-01
EP2670245A1 (en) 2013-12-11
EP2670245A4 (en) 2014-07-02
CA2825700A1 (en) 2012-08-09
WO2012106569A1 (en) 2012-08-09
JP2014504648A (ja) 2014-02-24
US9504675B2 (en) 2016-11-29
US20130338196A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
AU2012212088B2 (en) Alpha-ketoheterocycles and methods of making and using
CA2780433C (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RU2634896C2 (ru) Новые модуляторы рецептора glp-1
KR102564946B1 (ko) 신규 glp-1 수용체 조절제
AU2012212088A1 (en) Alpha-ketoheterocycles and methods of making and using
EP3782991A1 (en) Novel modulators of sphingosine phosphate receptors
CN104395309B (zh) 环状桥头醚dgat1抑制剂
CN115403570B (zh) μ-阿片受体激动剂及其制备方法和在医药领域的应用
EA025672B1 (ru) Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
JP6985271B2 (ja) アルキニルジヒドロキノリンスルホンアミド化合物
EP3774722B1 (en) Opioid receptor modulators and products and methods related thereto
KR20110010777A (ko) 스핑고신 포스페이트 수용체의 신규한 모듈레이터
IL297139A (en) Modulators of mas-related g-protein receptor x4 and related products and methods
RU2672468C1 (ru) Производные аза-адамантанов и их применение
WO2022074587A1 (en) Mu-opioid receptor agonists and uses therefor
WO2014018859A1 (en) Klf5 modulators
US9321728B2 (en) Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired